
Swedish immuno-oncology firm Alligator Bioscience (STO: ATORX) has announced the appointment of Johan Giléus as Alligator’s new chief executive (CEO), effective 1 January 2027.
The appointment follows Alligator’s strategic refocusing towards its financial interest in HLX22, as announced on July 23, 2026. Johan Giléus succeeds Søren Bregenholt, who will remain CEO until December 31, 2026. Johan Giléus will continue in parallel as CFO. Following the transition, Alligator will operate with a minimal organisation, supported by the Board of Directors and external consultants.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze